Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Short-term Investments: 2011-2025

Historic Short-term Investments for Abeona Therapeutics (ABEO) over the last 7 years, with Sep 2025 value amounting to $124.2 million.

  • Abeona Therapeutics' Short-term Investments rose 32.20% to $124.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $124.2 million, marking a year-over-year increase of 32.20%. This contributed to the annual value of $74.4 million for FY2024, which is 96.97% up from last year.
  • Per Abeona Therapeutics' latest filing, its Short-term Investments stood at $124.2 million for Q3 2025, which was up 100.43% from $62.0 million recorded in Q2 2025.
  • Abeona Therapeutics' Short-term Investments' 5-year high stood at $124.2 million during Q3 2025, with a 5-year trough of $11.0 million in Q1 2022.
  • Its 3-year average for Short-term Investments is $64.4 million, with a median of $62.0 million in 2025.
  • In the last 5 years, Abeona Therapeutics' Short-term Investments crashed by 85.34% in 2021 and then skyrocketed by 294.42% in 2023.
  • Over the past 5 years, Abeona Therapeutics' Short-term Investments (Quarterly) stood at $12.1 million in 2021, then soared by 213.85% to $37.9 million in 2022, then declined by 0.47% to $37.8 million in 2023, then skyrocketed by 96.97% to $74.4 million in 2024, then soared by 32.20% to $124.2 million in 2025.
  • Its Short-term Investments stands at $124.2 million for Q3 2025, versus $62.0 million for Q2 2025 and $68.2 million for Q1 2025.